“Currently the world capability is somewhere less than 500 million doses of vaccine with, you know, close to 6 billion people in the world. In addition, the dose that's required to induce an immune response with this particular vaccine is a significantly higher dose than the dose that you use to protect against the standard run-of-the-mill seasonal flu.”
“We are tending much more towards making sure that we have pharmaceutical plants that are located on U.S. soil, so that we don't have a situation where if you have a global pandemic, then countries would obviously be nationalizing [their] factories. So, we want to work with other companies. We want to work with other countries. We want to work with international as well as domestic companies, but we don't want to have everything that we are doing be done outside of the United States, which is almost what is the situation right now.”
“It isn't an absolute, but you certainly can say that the chances of containing spread among bird flocks in developed nations that have good agricultural capabilities and controls, to identify rapidly and cull and eliminate the sick chickens to prevent spread . . . is much better than in some other developing nations.”
“I don't think that the resources of the western European countries are going to implode because of this. But you see disaster striking, economically and otherwise, when you get into countries such as in Africa and other developing nations in which they don't have the resources to handle this.”
“We're aiming at 20-million doses of a pre-pandemic vaccine but to develop the capacity to be able to make 300-million doses within six months of when we ultimately get the latest version of it that is the real killer.”
